Top

Category: Pricing


Pricing, Regulations

FDA Moves Forward with State Drug Import Plans

May 31, 2022

Via: Biopharm International

Despite a long history of difficulties in this area, FDA once again is taking steps to facilitate the import of less costly prescription drugs from Canada by states, Indian Tribes, and other entities. The Canadian government has objected to the […]


Pricing, Regulations

Insulin price caps on the horizon as Senate leader plans vote

March 23, 2022

Via: Pharmaphorum

Senate Majority Leader Chuck Schumer said yesterday that a vote on legislation which would introduce the cap – already backed in a House of Representatives vote last November – would take place this spring after the April recess. If passed, […]


Pricing, Regulations

How does rare disease prevalence impact drug pricing in England?

February 4, 2022

Via: Pharmaphorum

Decision makers in the healthcare industry including payers, especially those who rely on the use of cost-effectiveness analysis (CEA) to evaluate new drugs, are often criticised for failing to capture the holistic value of drugs in their health technology assessments […]


Pricing, Regulations

Biogen takes axe to Aduhelm price in a bid to drive take-up

December 20, 2021

Via: Pharmaphorum

The price reduction for Aduhelm (aducanumab) comes into play from 1 January and comes on the back of the “feedback of our stakeholders,” said the biotech’s chief executive Michel Vounatsos. “Too many patients are not being offered the choice of […]


Pricing, Regulations

Democrats agree last-ditch deal to save drug pricing plans

November 4, 2021

Via: Pharmaphorum

A new stripped back proposal has won over rebel Democrats whose earlier opposition led the plan to be shelved, despite being a longstanding pillar of Democrat policy and one of Joe Biden’s campaign pledges. Notable holdouts – including Senator Kyrsten […]


Pricing, Regulations

With D.C. drug pricing talks up in the air, the ‘endgame’ could still ‘have a bite,’ analyst says

October 6, 2021

Via: FiercePharma

With Democrats in Washington debating the specifics of the president’s infrastructure program, the pharmaceutical industry may be able to squeak out a much-desired drug pricing win. As the negotiations unfold, Politico reports that the party leadership may have to abandon […]


FDA, Pricing, Regulations

To lower drug prices, Senate leaders, FDA urge U.S. Patent and Trademark Office to alter patent processes

September 14, 2021

Via: FiercePharma

The Senate and the FDA are appealing to the U.S. Patent and Trademark Office (USPTO) to examine how it can limit the ability of pharmaceutical companies to leverage patent strategies to extend their drug monopolies. In separate letters last week […]


Pricing, Regulations

Biden Highlights Drug Pricing Reforms to Advance Legislative Agenda

August 13, 2021

Via: Biopharm International

The White House is looking to pay for some of its prime social and health initiatives by reducing outlays for prescription drugs, according to an announcement by President Biden that supports several leading drug-price control policies strongly backed by Democrats. […]


Pricing, Regulations

Biden’s July Executive Order Includes Drug Pricing Provisions. But Will They Do Enough?

July 19, 2021

Via: Kaiser Health News

President Joe Biden’s executive order of July 9 included various steps toward making good on campaign promises to take on pharmaceutical companies by allowing the importation of prescription drugs and curbing the high cost of medicines. These issues were key […]


Pricing, Regulations

Congress has a ‘time-limited window’ to shake up drug pricing, employers, health groups say

July 14, 2021

Via: FiercePharma

A chance for meaningful drug pricing reform is upon us, dozens of purchasers, healthcare and employer groups contend. But Congress needs to capitalize on its “time-limited” opportunity, or the problem could stagnate or worsen. In a letter to a bipartisan […]


FDA, Pricing, Regulations

Amid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’

June 24, 2021

Via: Pharmaphorum

In a joint statement with Aduhelm (aducanumab) development partner Eisai, Biogen said it is expecting slow take-up of the drug and an eligible patent population of around 1-2 million people with mild Alzheimer’s in the US, saying it has no […]


Pricing, Regulations

Drug rebates were associated with higher out-of-pocket costs for patients

June 16, 2021

Via: Medical News

Federal agencies that regulate drug pricing and healthcare insurance are concerned that an industry practice of using rebates to lower drug costs for insurers has led to increases in list prices and out-of-pockets costs for patients. To investigate whether patients […]